Navigation Links
SIRIUS OutQ Honors International Day of AIDS Awareness
Date:11/28/2007

'OutQ in the Morning with Larry Flick' presents World AIDS Day Special

exclusively on SIRIUS Satellite Radio Interview with Madonna and exclusive performances from Cyndi Lauper, Indigo

Girls, Travis, Joss Stone, Erasure's Andy Bell and others

NEW YORK, Nov. 28 /PRNewswire-FirstCall/ -- SIRIUS Satellite Radio (Nasdaq: SIRI) today announced that it will honor World AIDS Day -- Saturday, December 1 -- with an exclusive broadcast event on SIRIUS OutQ 109, the nation's first and only 24/7 GLBT Radio channel. World AIDS Day 2007: A Celebration of Life and Hope will be hosted by OutQ in the Morning's Larry Flick from Noon - 6 pm ET.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991118/NYTH125 )

Flick will preside over the live six-hour event, interspersing exclusive musical performances with discussions with medical experts, pioneering activists, and SIRIUS listeners sharing their stories and perspectives on the ongoing battle against HIV/AIDS and the progress being made across the GLBT community.

This extraordinary event unites world-renowned musicians, leaders from the GLBT community, and listeners from the SIRIUS OutQ audience for a broadcast devoted entirely to the HIV/AIDS epidemic. The broadcast will include an interview with Madonna and exclusive performances by Cyndi Lauper, Indigo Girls, Travis, Joss Stone, Erasure's Andy Bell, Jimmy Somerville, Marc Cohn, Leann Rimes, Littlehorse, and others.

World AIDS Day is annually observed on December 1st and is dedicated to raising awareness of the global AIDS pandemic caused by the spread of HIV infection. Since World AIDS Day orig
'/>"/>

SOURCE SIRIUS Satellite Radio
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. SIRIUS Satellite Radio to Launch Doctor Radio, a Groundbreaking, 24/7 Health and Wellness Channel, in Partnership With NYU Medical Center
2. The African Medical and Research Foundation (AMREF) Honors Merck & Co., Inc. with Global Corporate Philanthropy Award
3. American Red Cross Honors Blood Collection Professionals During Blood Collectors Week 2007
4. Forbes Honors Susan G. Komen for the Cure Founder as Trailblazer
5. Eight Michigan HMOs, Two Providers, Take Top Honors for Quality Health Care
6. AMA Foundation Honors Hawaii Physician
7. Nobel Honors 3 Former March of Dimes Prize Recipients
8. Research!America Honors Univ. of Chicago Economists for Study Showing Economic Impact of HIV/AIDS Drug Development
9. Hazelden Honors Stephen I. Sadove, Chairman and CEO of Saks Fifth Avenue at its New York Awards Dinner to Benefit Youth and Families
10. GNC Honors Herb Day Tomorrow (and All Month Long)
11. THA Honors Nine Legislators for Contributions to Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2008)...y 21 /PRNewswire-FirstCall/ -- Aflac Incorporated,...presentation at the Sanford,C. Bernstein & Co., LL...nce,2008., President and Chief Financial Officer ...ted, and he is scheduled to make a presentation on...orated presentation, Mr.,Cloninger will discuss th...
(Date:5/21/2008)...d SILVER SPRING, Md., May 21 /PRNewswire-USNewswir... (ADAA),( http://www.adaa.org ) and The HealthCent... announced that ADAA will join,HealthCentral,s gro...and,health experts dedicated to helping people suf... advice and support they need to cope with the,con...
(Date:5/21/2008)...s 1st quarter profit, enhanced operations and new ...ELES, May 21 /PRNewswire-FirstCall/ -- InstaCare C...butor of at-home testing diagnostics,for the chron...eveloper of,patent-pending technologies for e-heal...s for the first quarter period-ended March 31, 200...
(Date:5/21/2008)... Adverse Events in TORCH Showed Frequency Highest ...ONTO and RESEARCH TRIANGLE PARK, N.C., May 21 /PRN...500/50 (fluticasone propionate and,salmeterol inha...er of,cardiovascular adverse events compared to ot...from the TOwards a Revolution in COPD Health,(TORC...
Breaking Medicine News(10 mins):Health News:Aflac Incorporated to Present at the Sanford C. Bernstein & Co., LLC Twenty-Fourth Annual Strategic Decisions Conference 2008 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 2Health News:The Anxiety Disorders Association of America and The HealthCentral Network Form Alliance to Develop New Online Resources for Anxiety Disorders 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 2Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 3Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 4Health News:InstaCare Corp. in Turnaround Reports 258% Revenues Increase in 1Q 2008 5Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 2Health News:Three-Year COPD Study Found No Increase in Cardiac Events With Advair(R) 500/50 3
...eille Guiliano’s bestseller ‘French Women Don’t Ge...nment figures, 5.9 million of France's 63.4 millio.... The figures have got the French government scra...e ways to come back to the former image of the sve...
...amin supplements and low fat dairy products in Bri...inding which was published// in The Journal of the...finding consumption of vitamin pills for a prolong...ality rate by 5% and low fat dairy may hamper the ...
...tain’s pay deals given by pay review bodies of the... millions of public sector workers across the coun...specially negative, in the medical sector. Healt... announced that GPs or family doctors will get a z...
Busting the Exam Blues
Other Medicine News:Health News:UK’s Health Services Totterin 2Health News:Busting the Exam Blues 2Health News:Busting the Exam Blues 3Health News:Busting the Exam Blues 4
(Date:5/21/2008)...ong Group of Leading Cancer Centers ...f., May 21 /- Endocare, Inc...ompany focused on the,development of minimally inv...tional radiologists for tissue and tumor ablation,...vasive method of freezing cancerous tumors,to dest...
(Date:5/20/2008)...- Today at the,World Congre...led "New,Perspectives in Atrial Fibrillation Manag... Cardiology, St George,s University of London,hig...ENA clinical trial,results, as the way forward in ...most common form of cardiac arrhythmia., To view ...
(Date:5/20/2008)... Digestive Disease Week(R) 2008, NATICK, Mass. an...on,Scientific Corporation (NYSE: BSX ) today anno...patient registry documenting favorable safety,and ...isualization System,which offers extensive visual...istry were presented by Yang K. Chen, M.D., Divisi...
(Date:5/20/2008)...y at Digestive Disease Week -, CAMBRIDGE, Mass. a...wood Pharmaceuticals, Inc. (formerly Microbia, Inc...ay announced the presentation of data,from a Phase...tudy,assessing the safety and efficacy of linaclot...alysis of these data indicate that linaclotide met...
Breaking Medicine Technology:Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting 2Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting 3Cryoablation Is Focus of 17 Clinical Studies at American Urological Association Annual Meeting 4ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 2ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 3ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 4ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 5ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 6Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientific's SpyGlass(R) Direct Visualization System 2Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientific's SpyGlass(R) Direct Visualization System 3Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientific's SpyGlass(R) Direct Visualization System 4Multi-Center Patient Registry Supports Safety and Clinical Utility of Boston Scientific's SpyGlass(R) Direct Visualization System 5Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 2Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 3Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 4Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 5Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results 6Association of Public Health Laboratories Applauds Signing of Newborn Screening Saves Lives Act 18422 1Association of Public Health Laboratories Applauds Signing of Newborn Screening Saves Lives Act 18422 2Scientists identify gatekeepers of breast cancer transition to invasive disease 18418 1Scientists identify gatekeepers of breast cancer transition to invasive disease 18418 2More efficient fuel cells thanks to a new catalyst 3185 1More efficient fuel cells thanks to a new catalyst 3185 2More efficient fuel cells thanks to a new catalyst 3185 3More efficient fuel cells thanks to a new catalyst 3185 4Protein May Trigger Colon Cancer 18411 1
...007 - Late breaking data,presented at the American... Sessions showed that, when used investigationally...combination with,metformin provided significant gl...d over 54 weeks in patients with type 2,diabetes. ...resented also showed that JANUVIA significantly im...
...E)--June 25, 2007--Gilead,Sciences, Inc. (Nasdaq:G...linical trial evaluating the company,s once-daily,...rate or tenofovir,DF) 300 mg as a potential treatm... met its primary efficacy endpoint. The data show,...daily antiviral,drug Hepsera(R) (adefovir dipivoxi...
Other Medicine Technology:Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 2Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 3Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 4Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 5Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 6Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 7Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 8Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 9Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 10Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 11Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 12Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 13Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 14Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 15Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 16Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 17Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 18Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 19Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 20Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 21Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 22Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 23Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 24Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 25Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 26Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 27Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 28Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 29Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 30Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 31Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes 32Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5
...r System combines precision with ease of operation...ns. The pneumatic motor powered system developed f...rocedures includes a drill, sagittal saw (extended...th available), reciprocating saw (extended length ...
Elmed Retract - Robot an single arm instrument, with extra long (10") horizontal extension for improved cephalad and anterior retraction. Retract - Robot (Retractor system) was designed to assist sur
Fortitude as a unique complement to the spinal concepts family of products.
As a unique complement to the spinal concepts family of products.
Medicine Products: